Discover a study that has revealed a new potential mechanism of understanding inflammation in ulcerative colitis.

Hunter Renfrow is mounting an NFL comeback after spending the 2024 season out of the league battling ulcerative colitis. Here ...

Recent years have seen significant advancements in UC treatment, offering renewed hope for patients seeking effective and ...

Explore the complexities of Ulcerative Colitis, its causes, diagnostic methods, and breakthrough treatments for better management.

Johnson & Johnson (J&J) has shared positive long-term results from a phase 3 trial of its dual-acting IL-23 inhibitor Tremfya ...

New long-term extension data from the Phase IIb/III QUASAR trial demonstrate that Tremfya (guselkumab) maintains durable ...

DelveInsight’s “Ulcerative Colitis Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth ...

Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC ...

Microbiotica unveils multiple mechanisms by which MB310, in clinical development for the treatment of ulcerative colitis, protects the intestinal barrierData presented at Digestive Disease Week in San ...

New Panthers wide receiver Hunter Renfrow on Thursday discussed his battle with ulcerative colitis, a chronic inflammatory ...

If you have ulcerative colitis (UC), you know that the physical symptoms—which include things like abdominal and rectal ...

Renfrow spent the 2024 season dealing with complications from an ulcerative colitis diagnosis. The autoimmune disease left the 29-year-old feeling lethargic as he battled high fevers and ...